VERTEX PHARMACEUTICALS INC (VRTX) Stock Analyst Ratings
USA - NASDAQ:VRTX - US92532F1003 - Common Stock
437.15 USD
+2.63 (+0.61%)
437.15 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 76% to VRTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 491.86. This target is 12.51% above the current price.
VRTX was analyzed by 39 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about VRTX.
In the previous month the buy percentage consensus was at a similar level.
VRTX was analyzed by 39 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | UBS | Maintains | Buy -> Buy |
| 2025-11-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-11-04 | Stifel | Maintains | Hold -> Hold |
| 2025-11-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-08 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-25 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-09-11 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-03 | Raymond James | Initiate | Market Perform |
| 2025-08-06 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-06 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-08-06 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-08-05 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-05 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-08-05 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-08-05 | UBS | Maintains | Buy -> Buy |
| 2025-08-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-08-05 | Stifel | Maintains | Hold -> Hold |
| 2025-08-05 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-20 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-17 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-05-06 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-05-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-06 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-05-06 | Needham | Reiterate | Hold -> Hold |
VERTEX PHARMACEUTICALS INC / VRTX FAQ
Can you provide the average price target for VERTEX PHARMACEUTICALS INC stock?
39 analysts have analysed VRTX and the average price target is 491.86 USD. This implies a price increase of 12.51% is expected in the next year compared to the current price of 437.15.
How do analysts rate VERTEX PHARMACEUTICALS INC (VRTX)?
The consensus rating for VERTEX PHARMACEUTICALS INC (VRTX) is 76.4103 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed VERTEX PHARMACEUTICALS INC (VRTX)?
The number of analysts covering VERTEX PHARMACEUTICALS INC (VRTX) is 39.